MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
TFX stock logo

TFX

Teleflex Incorporated

$137.71
-1.03
 (-0.74%)
Exchange:  NYSE
Market Cap:  6.096B
Shares Outstanding:  31.667M
Delayed data
Calculate TFX Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Instruments & Supplies
   
CEO:  Jason Weidman
Full Time Employees:  15500
Address: 
550 East Swedesford Road
Wayne
PA
19087-1603
US
Website:  https://www.teleflex.com
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the “Arrow” brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex’s interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue2,974,4893,047,3241,992,713
Gross Profit1,646,9311,702,6791,120,754
EBITDA761,212433,623302,514
Operating Income506,313151,013255,804
Net Income356,32869,675-905,640

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets7,532,5467,097,9146,947,239
Total Liabilities3,091,5582,819,7743,822,471
Total Stockholders Equity4,440,9884,278,1403,124,768
Total Debt1,926,3721,755,025184,210
Cash and Cash Equivalents222,848290,188378,564

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow510,638635,73996,682
Capital Expenditure-91,442-126,4340
Free Cash Flow419,196509,30596,682
Net Income356,32869,675-905,640
Net Change in Cash-69,186104,80275,031

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)2,706,653.057Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,747,647.219Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)2,728,333.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)603,983.357Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)613,131.109Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)608,821.261Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)630,143.284Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)642,580.581Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)636,720.843Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)874,909.101Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)888,160.213Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)881,917.118Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)14.240Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)14.370Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)14.090Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)4Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
3.047B  ?P/S
 (TTM)
: 
2.36
?Net Income
 (TTM)
: 
69.675M  ?P/E
 (TTM)
: 
-5.96
?Enterprise Value
 (TTM)
: 
8.718B  ?EV/FCF
 (TTM)
: 
22.32
?Dividend Yield
 (TTM)
: 
0.98%  ?Payout Ratio
 (TTM)
: 
-5.82%
?ROE
 (TTM)
: 
-31.83%  ?ROIC
 (TTM)
: 
1.3%
?Net Debt
 (TTM)
: 
1.482B  ?Debt/Equity
 (TTM)
: 
0.99
?P/B
 (TTM)
: 
2.08  ?Current Ratio
 (TTM)
: 
2.6

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
19.13Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates TFX intrinsic value between $156.22 – $159.13 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about TFX valuation

Is Teleflex Incorporated (TFX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Teleflex Incorporated (TFX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is TFX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TFX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is TFX’s P/E ratio?

You can see TFX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for TFX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is TFX a good long-term investment?

Whether TFX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

TFX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.74
MARKETSnap

Trading Metrics:

Open: 136.55   Previous Close: 138.74
Day Low: 136.55   Day High: 138.36
Year Low: 100.18   Year High: 145
Price Avg 50: 133.2   Price Avg 200: 122.05
Volume: 126861   Average Volume: 672471

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

TFX or PEN: Which Is the Better Value Stock Right Now?
26-08-2026 12:41
TFX or PEN: Which Is the Better Value Stock Right Now?
Why Teleflex (TFX) International Revenue Trends Deserve Your Attention
10-08-2026 10:16
Why Teleflex (TFX) International Revenue Trends Deserve Your Attention
Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates
06-08-2026 09:21
Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates
Teleflex Announces Second Quarter 2026 Earnings Conference Call Information
23-07-2026 06:30
Teleflex Announces Second Quarter 2026 Earnings Conference Call Information
Teleflex Publishes 2025 Global Impact Report
07-07-2026 06:30
Teleflex Publishes 2025 Global Impact Report
Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold
23-06-2026 06:30
Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read